国民保健体系正在启动220万英镑的肝透析装置试验,以70%的死亡率治疗致命肝脏疾病。 The NHS is launching a £2.2 million trial of a liver dialysis device to treat a deadly liver condition with a 70% death rate.

国民保健体系正在启动220万英镑的 Dialive装置试验,这是一种肝透析机,用于治疗急性慢性肝功能衰竭(ACLF),这是一个死亡率高的严重疾病。 The NHS is launching a £2.2 million trial of the Dialive device, a liver dialysis machine, to treat acute-on-chronic liver failure (ACLF), a severe condition with high mortality. 从2026年初开始,联合王国13家医院的72名重病患者将接受治疗,过滤毒素,替换受损蛋白质,以支持肝脏恢复。 Starting in early 2026, 72 critically ill patients across 13 UK hospitals will receive the treatment, which filters toxins and replaces damaged proteins to support liver recovery. ACLF通常与肥胖症、酒精和肝炎有关,在28天内死亡率达到70%,而且很少有移植选择。 ACLF, often linked to obesity, alcohol, and hepatitis, has a 70% death rate within 28 days and few transplant options. 早期研究表明,比标准护理更多的病人患 Dialive 逆转肝功能衰竭。 Early studies showed Dialive reversed liver failure in more patients than standard care. 该试验旨在确认其在现实世界环境中的有效性,有可能提供突破性治疗并减少对移植的依赖。 The trial aims to confirm its effectiveness in real-world settings, potentially offering a breakthrough treatment and reducing reliance on transplants.